Payment overview · 2025
General Payments
$1,266.47
54 reported records · 15 companies
Healthcare provider profile · identity verified
Enrique Ramos, M.D.,
Allopathic & Osteopathic Physicians|Family Medicine · GARDENA, CA · NPI 1477545531
Verified facts
What the public records show
CMS Open Payments records show Enrique Ramos, M.D., received $1,266.47 in general payments during 2025 across 54 reported records.
Merck Sharp & Dohme LLC accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Nexletol, Ozempic, Rybelsus, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $219.35 | 17.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $209.46 | 16.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.43 | 11.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $120.19 | 9.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.84 | 8.1% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $76.61 | 6.0% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $74.01 | 5.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.40 | 5.6% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.08 | 4.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.74 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.47 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.69 | 2.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.28 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.29 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.63 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,266.47 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $219.35 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $209.46 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.80 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.04 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.90 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $77.00 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $76.61 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $74.01 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.40 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.27 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $58.27 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $55.08 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $45.74 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 214 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 71 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 33 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
41 | 30 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
214 | 66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 28 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 721 | 229 |
| Metformin Hcl | Metformin Hcl | 531 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 143 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 105 |
| Simvastatin | Simvastatin | 316 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 72 |
| Lisinopril | Lisinopril | 277 | 85 |
| Pioglitazone Hcl | Pioglitazone Hcl | 274 | 83 |
| Losartan Potassium | Losartan Potassium | 270 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 37 |
| Omeprazole | Omeprazole | 239 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 79 |
| Tramadol Hcl | Tramadol Hcl | 216 | 66 |
| Farxiga | Dapagliflozin Propanediol | 214 | 66 |
| Gabapentin | Gabapentin | 195 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 54 |
| Alprazolam | Alprazolam | 177 | 32 |
| Montelukast Sodium | Montelukast Sodium | 169 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 167 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 56 |
| Pregabalin | Pregabalin | 142 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 137 | 45 |
| Ezetimibe | Ezetimibe | 132 | 45 |
| Glipizide | Glipizide | 132 | 42 |
| Furosemide | Furosemide | 127 | 43 |
| Clonazepam | Clonazepam | 123 | 26 |
| Ozempic | Semaglutide | 122 | 30 |
| Ibuprofen | Ibuprofen | 118 | 44 |
| Temazepam | Temazepam | 118 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 35 |
| Alendronate Sodium | Alendronate Sodium | 112 | 32 |
| Mirtazapine | Mirtazapine | 110 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 32 |
| Famotidine | Famotidine | 102 | 36 |
| Clonidine Hcl | Clonidine Hcl | 96 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 93 | 23 |
| Carvedilol | Carvedilol | 92 | 26 |
| Sertraline Hcl | Sertraline Hcl | 91 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 32 |
| Azithromycin | Azithromycin | 84 | 67 |
| Risperidone | Risperidone | 82 | 22 |
| Eliquis | Apixaban | 80 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 26 |
| Benazepril Hcl | Benazepril Hcl | 74 | 19 |
| Jardiance | Empagliflozin | 73 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Linzess | Linaclotide | 71 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 32 |
| Trulicity | Dulaglutide | 65 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 64 | 22 |
| Hydrocortisone | Hydrocortisone | 62 | 35 |
| Mounjaro | Tirzepatide | 61 | 20 |
| Finasteride | Finasteride | 60 | 19 |
| Potassium Chloride | Potassium Chloride | 60 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 19 |
| Prednisone | Prednisone | 58 | 24 |
| Lorazepam | Lorazepam | 57 | 11 |
| Atenolol | Atenolol | 55 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Diazepam | Diazepam | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 52 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 24 |
| Carisoprodol | Carisoprodol | 50 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 28 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 13 |
| Megestrol Acetate | Megestrol Acetate | 48 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 42 |
| Naproxen | Naproxen | 46 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Allopurinol | Allopurinol | 44 | 12 |
| Prolia | Denosumab | 41 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 14 |
| Myrbetriq | Mirabegron | 40 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 31 | 11 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Lyrica | Pregabalin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Meprobamate | Meprobamate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,266.47 · 54 records | Merck Sharp & Dohme LLC | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, CREON, EDARBI, EVENITY, FARXIGA, FASENRA, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, NEXLETOL, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, Veozah, Wegovy, ZORYVE, ZTLido | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error